ZA200710559B - Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment of urogenital cancer and its metastasis - Google Patents

Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment of urogenital cancer and its metastasis

Info

Publication number
ZA200710559B
ZA200710559B ZA200710559A ZA200710559A ZA200710559B ZA 200710559 B ZA200710559 B ZA 200710559B ZA 200710559 A ZA200710559 A ZA 200710559A ZA 200710559 A ZA200710559 A ZA 200710559A ZA 200710559 B ZA200710559 B ZA 200710559B
Authority
ZA
South Africa
Prior art keywords
metastasis
treatment
pharmaceutical compositions
sodium salt
arsenous acid
Prior art date
Application number
ZA200710559A
Other languages
English (en)
Inventor
Rademaker Bernardus
Original Assignee
Komipharm Int Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Komipharm Int Co Ltd filed Critical Komipharm Int Co Ltd
Publication of ZA200710559B publication Critical patent/ZA200710559B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Luminescent Compositions (AREA)
ZA200710559A 2005-05-09 2007-12-04 Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment of urogenital cancer and its metastasis ZA200710559B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05076071A EP1721615A1 (en) 2005-05-09 2005-05-09 Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis

Publications (1)

Publication Number Publication Date
ZA200710559B true ZA200710559B (en) 2008-10-29

Family

ID=35197739

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200710559A ZA200710559B (en) 2005-05-09 2007-12-04 Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment of urogenital cancer and its metastasis

Country Status (23)

Country Link
US (2) US20090011047A1 (pt)
EP (5) EP1721615A1 (pt)
JP (1) JP5026408B2 (pt)
KR (3) KR20160035101A (pt)
CN (2) CN101277707A (pt)
AR (1) AR054448A1 (pt)
AU (1) AU2006244767B2 (pt)
BR (1) BRPI0608716A2 (pt)
CA (3) CA2840609C (pt)
CY (2) CY1113475T1 (pt)
DK (2) DK1885380T3 (pt)
ES (2) ES2394264T3 (pt)
HU (1) HUE046029T2 (pt)
IL (3) IL187220A (pt)
LT (1) LT3067068T (pt)
PL (2) PL1885380T3 (pt)
PT (1) PT1885380E (pt)
RU (1) RU2401662C2 (pt)
SG (5) SG177983A1 (pt)
SI (2) SI3067068T1 (pt)
TW (5) TWI386214B (pt)
WO (1) WO2006121280A1 (pt)
ZA (1) ZA200710559B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8945505B2 (en) * 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
US20090246291A1 (en) 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
US20120045520A1 (en) * 2008-08-21 2012-02-23 Sang Bong Lee Pharmaceutical composition comprising arsenite for the treatment of malignancy
PT2475362T (pt) * 2009-09-10 2019-05-27 Kominox Inc Terapia especifica para celulas estaminais cancerigenas e para 0 cancro resistente a medicamentos
BR112012008310A2 (pt) * 2009-09-18 2017-06-06 Kominox Inc métodos para tratamento de tumores cerebrais
WO2011086137A1 (en) 2010-01-13 2011-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Promyelocytic leukemia protein as a redox sensor
RU2602937C2 (ru) * 2011-01-11 2016-11-20 Универзитет Базель Комбинация сиросингопина и митохондриальных ингибиторов для лечения рака и для иммуносупрессии
US20120251628A1 (en) * 2011-03-30 2012-10-04 Young Joo Min Compositions and methods for treatment of cancer
KR101309844B1 (ko) * 2013-03-15 2013-09-23 박상채 항암 활성 증진용 한약재 및 이의 제조방법
RU2618405C1 (ru) * 2015-12-31 2017-05-03 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ определения продолжительности адъювантной химиотерапии при местно-распространенном колоректальном раке с метастазами в регионарные лимфоузлы после радикальных оперативных вмешательств
US10806768B2 (en) * 2016-05-26 2020-10-20 Stephen N. Pitcher Composition for promoting metallothionein production
ES2964979T3 (es) 2016-12-01 2024-04-10 Eupharma Pty Ltd Composiciones de arsénico
EP3758686B1 (en) 2018-02-26 2024-11-06 R.P. Scherer Technologies, LLC Pharmaceutical dosage form for an emulsion of simethicone and loperamide
AU2019239671B2 (en) * 2018-03-22 2025-02-27 Komipharm International Australia Pty Ltd Pharmaceutical composition comprising meta arsenite and method of manufacture
WO2019234112A1 (en) * 2018-06-05 2019-12-12 Katholieke Universiteit Leuven Combination treatment of arsenic oxide and antiandrogens
IL295648A (en) * 2020-02-16 2022-10-01 Komipharm Int Australia Pty Ltd treatment method
KR20220020633A (ko) * 2020-08-12 2022-02-21 이상봉 탈모방지 또는 발모촉진용 주사제 조성물
KR20220020635A (ko) * 2020-08-12 2022-02-21 이상봉 탈모방지 또는 발모촉진용 외용제 조성물
KR20220020637A (ko) * 2020-08-12 2022-02-21 이상봉 항암화학요법이나 방사선요법으로 인한 암 환자의 탈모증을 포함한 탈모증 환자에 대하여 탈모를 방지하고 발모를 촉진하는 메타아르세나이트의 염을 함유하는 경구 투여용 약학적 조성물
CN112336746A (zh) * 2020-10-23 2021-02-09 内蒙古科技大学包头医学院 一种膀胱癌灌注化疗药物及其应用
CN116549741B (zh) * 2022-01-29 2025-04-11 中国科学院上海硅酸盐研究所 一种具有抑癌抗菌作用的表面改性镍钛合金材料及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
FR2431686A1 (fr) 1978-07-20 1980-02-15 Nestle Sa Soc Ass Tech Prod Mecanisme de dosage et d'equilibrage et machine de remplissage comprenant un tel mecanisme
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
KR930001917A (ko) * 1991-07-26 1993-02-22 김두석 악성 종양 치료제의 제조방법
EP0804928B1 (en) * 1994-02-18 2004-10-20 Tamara Vasilievna Vorobieva Agent having an immunomodulating effect and reducing disturbed functioning of the tissue cell propagation regulating system
RU2035181C1 (ru) * 1994-02-18 1995-05-20 Тамара Васильевна Воробьева Средство для лечения лейкозов и способ лечения лейкозов
JP2001519366A (ja) * 1997-10-15 2001-10-23 ポーラクス バイオファーマシュティカルズ，インコーポレーテッド ヒ素化合物を用いた、原発性および転移性の腫瘍性疾患を治療するための組成物および方法
IL136051A0 (en) 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
KR20020083678A (ko) * 2001-04-28 2002-11-04 주식회사 한국미생물연구소 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물
TW200408407A (en) 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
EP1496918B1 (en) * 2002-04-10 2023-02-08 Komipharm International Co., Ltd. Use of sodium meta-arsenite for the treatment of tumours
KR100632250B1 (ko) * 2004-02-16 2006-10-11 정태호 비소 화합물을 유효성분으로 하는 항암제
US20060104292A1 (en) 2004-11-15 2006-05-18 Gupta Vivek G System and methods for supporting multiple communications interfaces with single client interface
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
US20090246291A1 (en) 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
PT2475362T (pt) 2009-09-10 2019-05-27 Kominox Inc Terapia especifica para celulas estaminais cancerigenas e para 0 cancro resistente a medicamentos

Also Published As

Publication number Publication date
JP5026408B2 (ja) 2012-09-12
SI3067068T1 (sl) 2020-02-28
EP2361628A1 (en) 2011-08-31
IL187220A0 (en) 2008-02-09
SI1885380T1 (sl) 2013-01-31
PL1885380T3 (pl) 2013-02-28
TWI386214B (zh) 2013-02-21
SG10201602555WA (en) 2016-05-30
SG175633A1 (en) 2011-11-28
US20090011047A1 (en) 2009-01-08
TW201615200A (zh) 2016-05-01
CN101277707A (zh) 2008-10-01
LT3067068T (lt) 2019-12-10
SG10202100785PA (en) 2021-02-25
EP2762145A1 (en) 2014-08-06
IL229975A0 (en) 2014-01-30
TWI574692B (zh) 2017-03-21
CA2840609A1 (en) 2006-11-16
DK3067068T3 (da) 2019-11-18
KR101413731B1 (ko) 2014-07-10
ES2754372T3 (es) 2020-04-17
TW201500046A (zh) 2015-01-01
AU2006244767B2 (en) 2011-06-16
KR20160035101A (ko) 2016-03-30
IL244728A0 (en) 2016-04-21
TWI522105B (zh) 2016-02-21
CA2926846A1 (en) 2006-11-16
KR20150085122A (ko) 2015-07-22
KR20080030559A (ko) 2008-04-04
CY1113475T1 (el) 2016-06-22
SG177983A1 (en) 2012-02-28
TW201540306A (zh) 2015-11-01
PL3067068T3 (pl) 2020-08-10
EP3067068A1 (en) 2016-09-14
US11464859B2 (en) 2022-10-11
IL187220A (en) 2014-11-30
TWI539957B (zh) 2016-07-01
TW201302208A (zh) 2013-01-16
BRPI0608716A2 (pt) 2010-12-07
HUE046029T2 (hu) 2020-01-28
EP3067068B1 (en) 2019-08-14
RU2007145489A (ru) 2009-06-20
WO2006121280A1 (en) 2006-11-16
AR054448A1 (es) 2007-06-27
CY1122522T1 (el) 2021-01-27
ES2394264T3 (es) 2013-01-30
RU2401662C2 (ru) 2010-10-20
EP1885380B1 (en) 2012-07-11
SG10201405278SA (en) 2015-05-28
CA2840609C (en) 2016-08-16
IL229975A (en) 2017-12-31
CN104758312A (zh) 2015-07-08
JP2008546640A (ja) 2008-12-25
EP1885380A1 (en) 2008-02-13
CA2926846C (en) 2019-04-02
EP1721615A1 (en) 2006-11-15
TW200716144A (en) 2007-05-01
DK1885380T3 (da) 2012-10-22
CA2608035C (en) 2015-02-17
US20160199411A1 (en) 2016-07-14
EP1885380A4 (en) 2009-02-18
CA2608035A1 (en) 2006-11-16
AU2006244767A1 (en) 2006-11-16
HK1109736A1 (en) 2008-06-20
PT1885380E (pt) 2012-10-11

Similar Documents

Publication Publication Date Title
IL229975A0 (en) Pharmaceutical compounds containing arsenoic acid, its sodium salt and its antecedents for the treatment of organ cancer and its metastases
IL185517A0 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
IL190137A0 (en) Crystals of laquinimod sodium, and process for the manufacture thereof
IL191832A0 (en) Pyridiazinone derivatives for the treatment of tumours
IL189737A0 (en) Pyrazine derivatives, their preparation and pharmaceutical compositions containing them
ZA200805163B (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer
IL197941A0 (en) Use of anilinopyrimidine derivatives for the preparation of pharmaceutical compositions for treating non-alcoholic liver diseases
IL187391A0 (en) Thiazole derivatives, their preparation and use and pharmaceutical compositions containing them
SI1860098T1 (sl) Nov derivat antranilne kisline ali sol le-tega
TW200724537A (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
UA91848C2 (ru) Применение соединений диосметина в лечении и предотвращении тромботическим патологиям
PL1863495T3 (pl) Sól wapniowa 1,6:2,3:4,5-tripirofosforanu mioinozytolu jako efektor allosteryczny hemoglobiny w leczeniu raka
IL186022A0 (en) Dermatological compositions and salts for the treatment of dermatological diseases
TWI367761B (en) Pharmaceutical composition containing hardly water soluble pharmaceutical substance
HUP0600293A2 (en) Zinc salt of rosuvastatine, process for its preparation and pharmaceutical compositions containing it
IL187655A0 (en) Anthranilic acid derivatives
IL187026A0 (en) Substituted acrylamide derivatives and pharmaceutical compositions containing the same
IL194094A0 (en) Stable pharmacuetical compositions of 2-aza-bicyclol[3.3.0]-octane-3-carboxylic acid derivatives
SI1707564T1 (sl) Indanil-piperazinski derivati, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
EP1867640A4 (en) MEANS FOR TREATING SOLID TUMORS
IL198848A0 (en) Sodium salt of disaccharide compound, method for producing the same, and use of the same
IL190230A0 (en) Derivatives of 2-aminthiazoles and 2-aminooxazoles, processes for their preparation and their use as pharmaceuticals
EP1984327A4 (en) IMPROVED METHOD FOR THE PRODUCTION OF CILASTATIN AND ITS SODIUM SALT
IL187419A0 (en) Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
IL188185A0 (en) Phenylpyridine derivatives, their manufacture and use as pharmaceutical agents